# The Safety, Dosimetry and Efficacy of 177Lu-FC516 in Patients With Prostate Cancer

> **NCT07542379** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **FindCure Biosciences (ZhongShan) Co., Ltd.** · enrollment: 13 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** 177Lu-FC516

## Key facts

- **NCT ID:** NCT07542379
- **Lead sponsor:** FindCure Biosciences (ZhongShan) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04
- **Primary completion:** 2027-05
- **Final completion:** 2027-10
- **Target enrollment:** 13 (ESTIMATED)
- **Last updated:** 2026-04-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07542379

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07542379, "The Safety, Dosimetry and Efficacy of 177Lu-FC516 in Patients With Prostate Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07542379. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*